The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19
Alessandro Gozzetti, Enrico Capochiani, Monica Bocchia
Topics & Concepts
RuxolitinibCoronavirus disease 2019 (COVID-19)CitationHematologyMedicine2019-20 coronavirus outbreakJanus kinaseInternal medicineLibrary scienceVirologyBone marrowComputer scienceDiseaseInfectious disease (medical specialty)OutbreakCytokineMyelofibrosisCOVID-19 Clinical Research StudiesCOVID-19 and healthcare impactsInflammasome and immune disorders